Press release: dupixent® late-breaking data from notus confirmatory phase 3 copd study presented at ats and published in nejm

Dupixent ® late-breaking data from notus confirmatory phase 3 copd study presented at ats and published in nejm notus results confirm landmark data from the phase 3 boreas study and show dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (copd) with evidence of type 2 inflammation data support the potential of dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for copd paris and tarrytown, n.y. may 20, 2024.
REGN Ratings Summary
REGN Quant Ranking